Business

Gilead prices COVID-19 drug candidate remdesivir at US$390/vial in US

Your ads will be inserted here by

Easy Plugin for AdSense.

Please go to the plugin admin page to
Paste your ad code OR
Suppress this ad slot.

Business

Gilead Sciences Inc said on Monday it has priced its COVID-19 treatment candidate remdesivir at US$390 per vial in the United States and other developed countries.

FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen during the outbreak of the coronavirus disease (COVID-19), in California

29 Jun 2020 07:25PM

Share this content

Bookmark

REUTERS: Gilead Sciences Inc said on Monday it has priced its COVID-19 treatment candidate remdesivir at US$390 per vial in the United States and other developed countries.

Based on current treatment patterns, the vastRead More – Source